arrow
W

Wei Ding

Department of Medicine
H指数:35
被引数:6,135

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparison of Frontline Therapies in Older Adults Age ≥ 80 Years With Chronic Lymphocytic Leukemia (CLL): A Mayo Clinic and Danish Nation-Wide Study

比较年龄≥80岁慢性淋巴细胞白血病(CLL)老年患者一线疗法:一项梅奥诊所与丹麦全国性研究

2025-06-180
PRE
Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era
LEUKEMIA
IF13.4
2024-12-100
PRE
Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis
2024-04-271
OAAI
Arti fi cial Intelligence Electrocardiography to Predict Atrial Fibrillation in Patients With Chronic Lymphocytic Leukemia
2024-04-012
OA
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia

免疫检查点抑制剂治疗慢性淋巴细胞白血病合并晚期黑色素瘤的疗效

2023-09-014
OA
Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia
2023-07-019
OA
DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study
2023-03-075
PRE
Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
2022-09-016
OAAI
Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?
2022-01-2811
OAAI
Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis
2021-11-0518
OA
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
LEUKEMIA
IF13.4
2021-07-1714
OAAI